In August 2023, the Danish pharmaceutical company Novo Nordisk became Europe’s largest company by market capitalization. The company has long held a dominant position in diabetes treatment. By a happy coincidence, it has been shown that the company’s new generation of diabetes medicine also works well to treat obesity. That’s what Affärsvärlden writes in an analysis on Monday.
In its main scenario, the newspaper sees a potential of 14 percent in the share in a couple of years.
“We lean towards Novo Nordisk being able to maintain a dominant position even in the long term in obesity treatment and type 2 diabetes. However, that conviction is not strong enough for us to take a position on the stock”, writes Affärsvärlden in its conclusion and leaves a neutral advice.
Henrik Ohlin
[email protected], 0703-21 06 99
News agency Finwire
